Cargando…

Receptor tyrosine kinase targeting in glioblastoma: performance, limitations and future approaches

From all central nervous system tumors, gliomas are the most common. Nowadays, researchers are looking for more efficient treatments for these tumors, as well as ways for early diagnosis. Receptor tyrosine kinases (RTKs) are major targets for oncology and the development of small-molecule RTK inhibi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alexandru, Oana, Horescu, Cristina, Sevastre, Ani-Simona, Cioc, Catalina Elena, Baloi, Carina, Oprita, Alexandru, Dricu, Anica
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Termedia Publishing House 2020
Materias:	Review Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7265959/ https://www.ncbi.nlm.nih.gov/pubmed/32514239 http://dx.doi.org/10.5114/wo.2020.94726

Ejemplares similares

The effect of Azo-dyes on glioblastoma cells in vitro
por: Sevastre, Ani-Simona, et al.
Publicado: (2023)

ELTD1—An Emerging Silent Actor in Cancer Drama Play
por: Sevastre, Ani-Simona, et al.
Publicado: (2021)

The Potential of Helianthin Loaded Into Magnetic Nanoparticles to Induce Cytotoxicity in Glioblastoma Cells
por: COSTACHI, ALEXANDRA, et al.
Publicado: (2021)

Combined Effects of Doxorubicin and Temozolomide in Cultured Glioblastoma Cells
por: BALOI, CARINA, et al.
Publicado: (2022)

The Effect of Β-Arrestin2 Overexpression Regarding Viability and Temozolomide Treatment in High-Grade Glioma Cells
por: OPRITA, ALEXANDRU, et al.
Publicado: (2022)

Glioblastoma Stem Cells—Useful Tools in the Battle against Cancer
por: Rodriguez, Silvia Mara Baez, et al.
Publicado: (2022)

Updated Insights on EGFR Signaling Pathways in Glioma
por: Oprita, Alexandru, et al.
Publicado: (2021)

Glioblastoma pharmacotherapy: A multifaceted perspective of conventional and emerging treatments (Review)
por: Sevastre, Ani-Simona, et al.
Publicado: (2021)

Platelet-Derived Growth Factor Receptor and Ionizing Radiation in High Grade Glioma Cell Lines
por: Alexandru, Oana, et al.
Publicado: (2019)

New perspectives in glioblastoma antiangiogenic therapy
por: Popescu, Alisa Madalina, et al.
Publicado: (2015)

In vitro evaluation of Axitinib and Sorafenib treatment in glioblastoma cell viability and morphology
por: Opriţa, Alexandru, et al.
Publicado: (2023)

An Overview of EGFR Mechanisms and Their Implications in Targeted Therapies for Glioblastoma
por: Rodriguez, Silvia Mara Baez, et al.
Publicado: (2023)

The Interference between SARS-CoV-2 and Tyrosine Kinase Receptor Signaling in Cancer
por: Purcaru, Oana-Stefana, et al.
Publicado: (2021)

Intracellular Pathways and Mechanisms of Colored Secondary Metabolites in Cancer Therapy
por: Sevastre, Ani-Simona, et al.
Publicado: (2022)

Epidermal growth factor, latrophilin, and seven transmembrane domain-containing protein 1 marker, a novel angiogenesis marker
por: Serban, Florentina, et al.
Publicado: (2015)

The Influence of EGFR Inactivation on the Radiation Response in High Grade Glioma
por: Alexandru, Oana, et al.
Publicado: (2018)

Dendritic cell immunotherapy versus bevacizumab plus irinotecan in recurrent malignant glioma patients: a survival gain analysis
por: Artene, Stefan-Alexandru, et al.
Publicado: (2016)

Biobanking in a Constantly Developing Medical World
por: Artene, Stefan-Alexandru, et al.
Publicado: (2013)

Oncogenic Signalling of Growth Factor Receptors in Cancer: Mechanisms and Therapeutic Opportunities
por: Dricu, Anica
Publicado: (2022)

Comparative effect of immunotherapy and standard therapy in patients with high grade glioma: a meta-analysis of published clinical trials
por: Artene, Stefan-Alexandru, et al.
Publicado: (2018)

The Rescue of the Romanian Health System by the Emergency Departments during the Fourth Wave of COVID-19 Pandemic
por: Oprita, Bogdan, et al.
Publicado: (2022)

Role of Receptor Tyrosine Kinases and Their Ligands in Glioblastoma
por: Carrasco-García, Estefanía, et al.
Publicado: (2014)

Plasma Levels of Glucose and Insulin in Patients with Brain Tumors
por: ALEXANDRU, OANA, et al.
Publicado: (2014)

Cancer Stem Cells: Biological Functions and Therapeutically Targeting
por: Ciurea, Marius Eugen, et al.
Publicado: (2014)

Transcriptomic Crosstalk between Gliomas and Telencephalic Neural Stem and Progenitor Cells for Defining Heterogeneity and Targeted Signaling Pathways
por: Deleanu, Roxana, et al.
Publicado: (2021)

Evaluation of Tyrosine Kinase Inhibitor Combinations for Glioblastoma Therapy
por: Joshi, Avadhut D., et al.
Publicado: (2012)

Receptor Tyrosine Kinase Signaling and Targeting in Glioblastoma Multiforme
por: Tilak, Manali, et al.
Publicado: (2021)

Data from numerical analysis, simulation and experimental determinations performed to verify the sizing of an unbalanced capacitive compensator for three-phase four-wires networks
por: Pană, Adrian, et al.
Publicado: (2019)

The Role of Hypoxia and SRC Tyrosine Kinase in Glioblastoma Invasiveness and Radioresistance
por: Torrisi, Filippo, et al.
Publicado: (2020)

Tyrosine Kinase Inhibitors in Adult Glioblastoma: An (Un)Closed Chapter?
por: Aldaz, Paula, et al.
Publicado: (2021)

Rituximab-Induced Kaposi Sarcoma in HIV-Negative Patients: A Narrative Review
por: Oprita, Alexandru, et al.
Publicado: (2023)

Tyrosine Kinase Inhibitors for Glioblastoma Multiforme: Challenges and Opportunities for Drug Delivery
por: Brar, Harpinder K., et al.
Publicado: (2022)

NRF2 connects Src tyrosine kinase to ferroptosis resistance in glioblastoma
por: Cirotti, Claudia, et al.
Publicado: (2023)

Sunitinib-Containing Carborane Pharmacophore with the Ability to Inhibit Tyrosine Kinases Receptors FLT3, KIT and PDGFR-β, Exhibits Powerful In Vivo Anti-Glioblastoma Activity
por: Alamón, Catalina, et al.
Publicado: (2020)

Sleep Deprivation-Induced Oxidative Stress in Rat Models: A Scoping Systematic Review
por: Neculicioiu, Vlad Sever, et al.
Publicado: (2023)

Co-survival of the fittest few: mosaic amplification of receptor tyrosine kinases in glioblastoma
por: Chen, Feng, et al.
Publicado: (2012)

A combination of tyrosine kinase inhibitors, crizotinib and dasatinib for the treatment of glioblastoma multiforme
por: Nehoff, Hayley, et al.
Publicado: (2015)

Clinical activity of the EGFR tyrosine kinase inhibitor osimertinib in EGFR-mutant glioblastoma
por: Makhlin, Igor, et al.
Publicado: (2019)

Novel Receptor Tyrosine Kinase Pathway Inhibitors for Targeted Radionuclide Therapy of Glioblastoma
por: Bolcaen, Julie, et al.
Publicado: (2021)

Receptor tyrosine kinases as druggable targets in glioblastoma: Do signaling pathways matter?
por: Qin, Anna, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_sk5vor4h8fd3aaq6ljalahncad